A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 3, 2016, Pages 578-588

  Hiniker, Susan M ^a   Reddy, Sunil A ^b   Maecker, Holden T ^b   Subrahmanyam, Priyanka B ^b   Rosenberg Hasson, Yael ^b   Swetter, Susan M ^a,c   Saha, Saurabh ^d   Shura, Lei ^a   Knox, Susan J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d 400 Technology Square   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; DERMATOLOGY; DISEASE CONTROL; ENZYME INHIBITION; IMMUNE SYSTEM; ONCOLOGY; T-CELLS;

CLINICAL INVESTIGATION; COMBINATION THERAPY; COMPLETE RESPONSE; CYTOTOXIC T LYMPHOCYTES; LABORATORY ASSESSMENT; METASTATIC MELANOMA; METHODS AND MATERIALS; PROGRAMMED CELL DEATHS;

PATIENT TREATMENT;

BIOLOGICAL MARKER; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IPILIMUMAB; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLITIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HYPOPHYSITIS; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIATION SAFETY; RADIOTHERAPY UNIT; RASH; SYSTEMIC THERAPY; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; MELANOMA; PROCEDURES; RADIOIMMUNOTHERAPY; SECONDARY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84990833621     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.07.005     Document Type: Conference Paper

References (16)

1. 1 Barrow, C., Browning, J., MacGregor, D., et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:3 Pt 1 (2006), 764–771.
2. 2 Postow, M.A., Callahan, M.K., Barker, C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
3. 3 Clemente, C.G., Mihm, M.C. Jr., Bufalino, R., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996), 1303–1310.
4. 4 Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
5. 5 Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
6. 6 Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
7. 7 Hiniker, S.M., Chen, D.S., Reddy, S., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 5 (2012), 404–407.
8. 8 Golden, E.B., Demaria, S., Schiff, P.B., et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1 (2013), 365–372.
9. 9 Reynders, K., Illidge, T., Siva, S., et al. The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41 (2015), 503–510.
10. 10 Twyman-Saint Victor, C., Rech, A.J., Maity, A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
11. 11 Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
12. 12 Wolchok, J.D., Hoos, A., O'Day, S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
13. 13 Weber, J., Thompson, J.A., Hamid, O., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15 (2009), 5591–5598.
14. 14 Postow, M.A., Chesney, J., Pavlick, A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
15. 15 Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
16. 16 Wolchok, J.D., Neyns, B., Linette, G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11 (2010), 155–164.